Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | CTSS | P25774 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | PHGDH | O43175 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5126103 | 1.00 | MAPT (0.52) | MAPTCTSSCTSKRAB9APOLB | |
| SCHEMBL14139306 | 0.86 | MAPT (0.52) | MAPTRAB9APOLBAKR1C3KDM4E | |
| SCHEMBL2162724 | 0.81 | CTSS (0.48) | MAPTCTSSCTSKRAB9APOLB | |
| SCHEMBL12196232 | 0.81 | MAPT (0.47) | MAPTRAB9APOLBAKR1C3SMN1; SMN2 | |
| SCHEMBL2162730 | 0.81 | CTSS (0.48) | MAPTCTSSCTSKRAB9APOLB | |
| SCHEMBL12196254 | 0.81 | CTSS (0.48) | MAPTCTSSCTSKRAB9APOLB | |
| SCHEMBL2162752 | 0.78 | MAPT (0.46) | MAPTCTSSRAB9APOLBHTT | |
| SCHEMBL2162758 | 0.78 | MAPT (0.46) | MAPTCTSSRAB9APOLBHTT | |
| SCHEMBL12400766 | 0.76 | MAPT (0.42) | MAPTRAB9APOLB | |
| SCHEMBL27672213 | 0.75 | MAPT (0.48) | MAPTRAB9APOLBAKR1C3PHGDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080021025-A1 | INHIBITORS OF CATHEPSIN S | LIU HONG | 2008-01-24 | — | — | US | disclosed |
| US-7297714-B2 | Selective in presence of at least one other cathepsin isozyme; such as (3-cyclopentyl-{[5-(3-fluoro-phenyl)-furan-2-carbonyl]-amino}-propionylamino)-4-oxo-butyric acid | IRM LLC (BM) | 2007-11-20 | — | — | US | disclosed |
| US-20050130959-A1 | Inhibitors of cathepsin S | IRM LLC (BM) | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021025-A1 | INHIBITORS OF CATHEPSIN S | CTSS, CTSB, CTSZ | MAPT 1757/4885CTSS 1/4885CTSK 9/4885 |
| US-20050130959-A1 | Inhibitors of cathepsin S | CTSS, CTSB, CTSZ | MAPT 1757/4885CTSS 1/4885CTSK 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.